Ratos: Lindab IPOLindab is going ahead with its planned IPO. The price range for the offer is set at SEK 93-110 per share. Ratos intends to sell up to 51% of its shares in Lindab in conjunction with the IPO, whereof up to 45% of Ratos's holding is part of the basic offering and the remaining 6% corresponds to an over-allotment option. Based on the consolidated value of Ratos's holding as of 30 September, the capital gain from the sale is expected to be SEK 1,000 million to 1,500 million. The final capital gain will be adjusted for Ratos's share of Lindab's profit until the date of the sale and exchange differences. The consolidated book value of Ratos's remaining holding will be between SEK 470 million and SEK 525 million, depending on how many shares are sold, based on the consolidated value as of 30 September. For further information regarding the Lindab IPO, please visit www.lindab.com/default.htm For further information, please contact:Arne Karlsson, CEO Ratos, +46 8 700 17 00Anna-Karin Celsing, Head of Corporate Communications Ratos, +46 70 399 62 39Kjell Åkesson, CEO Lindab, +46 431 850 00 Financial calendar from Ratos: Year-end report 200622 February 2007Annual General Meeting11 April 2007Interim report January-March9 May 2007Interim report January-June21 August 2007 Interim report January-September 9 November 2007 Ratos is a listed private equity company. The business concept is to maximise shareholder value over time by investing in, developing and divesting primarily unlisted companies. Ratos thus offers stock market players a unique investment opportunity. The equity of Ratos's investments is approximately SEK 9 billion. Ratos's holdings include Alimak Hek, Arcus, Anticimex, Bisnode, Bluegarden, Camfil, DIAB, GS-Hydro, Haendig, Haglöfs, HL Display, Hägglunds Drives, Inwido, Jøtul, Lindab, Medifiq Healthcare, Superfos and Other holdings.Attachment: Press release (PDF)Text version / Internet version / Print / Close
